A Phase 1, Randomzied, Double-blind, Third-party Open Placebo-controlled, Dose Escalating Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Intravenous And Multiple Subcutaneous And Intravenous Doses Of Pf-06480605 In Healthy Subjects

Trial Profile

A Phase 1, Randomzied, Double-blind, Third-party Open Placebo-controlled, Dose Escalating Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Intravenous And Multiple Subcutaneous And Intravenous Doses Of Pf-06480605 In Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 05 May 2016

At a glance

  • Drugs PF 6480605 (Primary) ; PF 6480605 (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer
  • Most Recent Events

    • 27 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 07 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 08 Oct 2014 Planned End Date changed from 1 Dec 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top